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Abstract Muscle wasting in cancer is a common and often
occult condition that can occur prior to overt signs of weight
loss and before a clinical diagnosis of cachexia can be made.
Muscle wasting in cancer is an important and independent
predictor of progressive functional impairment, decreased
quality of life, and increased mortality. Although several ther-
apeutic agents are currently in development for the treatment
of muscle wasting or cachexia in cancer, the majority of these
agents do not directly inhibit muscle loss. Selective androgen
receptor modulators (SARMs) have the potential to increase
lean body mass (LBM) and hence muscle mass, without the
untoward side effects seen with traditional anabolic agents.
Enobosarm, a nonsteroidal SARM, is an agent in clinical de-
velopment for prevention and treatment of muscle wasting in
patients with cancer (POWER 1 and 2 trials). The POWER
trials are two identically designed randomized, double-blind,
placebo-controlled, multicenter, and multinational phase 3 tri-
als to assess the efficacy of enobosarm for the prevention and
treatment of muscle wasting in subjects initiating first-line
chemotherapy for non-small-cell lung cancer (NSCLC). To
assess enobosarm’s effect on both prevention and treatment
of muscle wasting, nominimumweight loss is required. These
pivotal trials have pioneered the methodological and regula-
tory fields exploring a therapeutic agent for cancer-associated
muscle wasting, a process hereby described. In each POWER
trial, subjects will receive placebo (n=150) or enobosarm
3 mg (n=150) orally once daily for 147 days. Physical func-
tion, assessed as stair climb power (SCP), and LBM, assessed
by dual-energy X-ray absorptiometry (DXA), are the co-
primary efficacy endpoints in both trials assessed at day 84.
Based on extensive feedback from the US Food and Drug
Administration (FDA), the co-primary endpoints will be ana-
lyzed as a responder analysis. To be considered a physical
function responder, a subject must have ≥10 % improvement
in physical function compared to baseline. To meet the defi-
nition of response on LBM, a subject must have demonstrated
no loss of LBM compared with baseline. Secondary endpoints
include durability of response assessed at day 147 in those
responding at day 84. A combined overall survival analysis
for both studies is considered a key secondary safety endpoint.
The POWER trials design was established with extensive clin-
ical input and collaboration with regulatory agencies. The ef-
ficacy endpoints are a result of this feedback and discussion of
the threshold for clinical benefit in patients at risk for muscle
wasting. Full results from these studies will soon be published
and will further guide the development of future anabolic
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Introduction
Cancer is a disease associated with severe muscle wasting
caused by a variety of neural, nutritional, pro-inflammatory,
and autocrine/endocrine factors that ultimately culminate in an
imbalance between anabolism and catabolism. Emerging ev-
idence suggests that muscle wasting in cancer can be an occult
condition, present in individuals with normal or even high
body weight [1]. Importantly, muscle wasting in cancer is
common and an independent predictor of poorer physical
function, higher incidence of chemotherapy-related toxicity,
shorter time to tumor progression, increased length of hospital
stay, and shorter survival [1–3].
Muscle wasting in cancer occurs across tumor sites and
stages and is more pronounced and prevalent in patients with
advanced gastrointestinal and/or lung cancer, where cachexia
is often manifested. Muscle wasting in cancer patients repre-
sents a significant unmet medical need, as at the time of diag-
nosis, 50 % of patients with advanced cancer will have skel-
etal muscle loss [4]. Furthermore, the proportion of patients
experiencing muscle wasting at some point during the course
of their malignancy increases to greater than 80 % [5]. In
addition, evidence suggests that up to 20 % of all cancer
deaths are directly caused by cachexia [6]. Muscle wasting
in patients with NSCLC has been associated with decreased
functional status, higher incidence of chemotherapy toxicity,
and shorter survival.
When muscle wasting is accompanied by weight loss, a
diagnosis of cachexia may bemade. Cancer cachexia has been
more recently defined as a complex syndrome characterized
by ongoing skeletal muscle loss with or without an accompa-
nying loss of fat mass [7, 8••]. This multifactorial syndrome
cannot be completely reversed with conventional methods of
nutritional supplementation or appetite stimulation and causes
progressive functional impairment [8••].
The prevalence and significance of muscle wasting in can-
cer, as well as the lack of an effective treatment for this con-
dition, underscore the importance of developing an effective
therapeutic approach for the prevention and treatment of
cancer-associated muscle wasting. Although megesterol ace-
tate has been approved in some countries for cancer cachexia,
the general consensus is that it has little effect on lean mass [9]
and, to date, no pharmacologic treatments are approved for the
prevention and treatment of muscle wasting. As muscle
wasting has been primarily studied under the auspices of can-
cer cachexia, most appetite stimulants, anti-inflammatory and
anabolic or nutritional agents have failed to effectively prevent
or reverse this condition. Increasing nutritional delivery of
energy may preserve or increase fat mass without increasing
muscle mass, which could paradoxically be detrimental to
patients [4, 10, 11•]. Some of the more successful attempts
at treating cachexia-associated muscle wasting in cancer have
resulted from anabolic androgenic steroids, which have been
shown to increase protein synthesis and lean body mass
(LBM) in wasting disorders [12–15]. However, in addition
to promoting anabolism, these agents also have unfavorable
androgenic effects including an increased risk of hepatic tox-
icity, acne, increased sebum production, and virilization and
hirsutism in women, and potential concerns related to benign
prostatic hyperplasia (BPH) and prostate cancer in men, that
may outweigh their benefits [12, 16]. Ideally, a treatment
should be able to produce anabolism selectively without the
accompanying androgenic side effects, which has led to in-
creased research on nonsteroidal, selective androgen receptor
modulators, or SARMs [17].
Need for a Novel Study Design
In contrast to the development of new chemotherapies, there
are no standard methods or outcomes for studying the preven-
tion and treatment of muscle wasting and a novel study design
was needed to demonstrate the clinical benefit of any thera-
peutic intervention for muscle wasting. In addition to
assessing the efficacy of a drug to prevent and treat muscle
wasting by measuring changes in physical function and LBM,
it is essential to include safety endpoints related to disease
burden and survival. Although the relationship between mus-
cle mass and physical function is still obscure (i.e., the mag-
nitude of LBM increase which is needed to promote an in-
crease in function), physical function endpoints that are reflec-
tive of activities of daily living may be used to determine the
clinical benefit associated with preserving or increasing LBM.
Quality of life (QoL) also needs to be assessed in these trials,
especially in patients who demonstrate a response on the phys-
ical function assessment. Available methods that measure the
impact of anorexia, fatigue, or cachexia on a patient’s quality
of life include the Functional Assessment of Cancer Therapy
(FACT) questionnaire and its subscales [18, 19].
Novel Drug: Enobosarm
Enobosarm (GTx-024; GTx, Inc., Memphis, TN) is an
orally bioavailable nonsteroidal SARM [20]. The poten-
tial of enobosarm for clinical utility was demonstrated
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by its selective activity in anabolic tissues at low doses
in preclinical trials [21]. In the clinical setting, the use
of enobosarm led to significant improvements in LBM
and physical function in a phase 2, double-blind,
placebo-controlled study in healthy postmenopausal
women and elderly men [20]. In a phase 2b, double
blind, placebo controlled study, enobosarm treatment
was well tolerated and led to significantly improved
LBM, physical function, and quality of life in men
older than 45 years and postmenopausal women with
non-small-cell lung cancer (NSCLC), colorectal cancer,
non-Hodgkin’s lymphoma, chronic lymphocytic leuke-
mia, or breast cancer [22••]. Androgenic adverse events,
including negative effects on the prostate, virilization
and hirsutism, have not been reported [20].
Building on these findings, the phase 3 Prevention and
treatment Of muscle Wasting in patients with cancER
(POWER) studies (POWER 1 and POWER 2) are designed
to assess the efficacy and safety of enobosarm for the preven-
tion and treatment of muscle wasting in patients undergoing
first-line chemotherapy for NSCLC, with the ultimate goal of
demonstrating the clinical benefit of enobosarm on physical
function and LBM. Consultation occurred with several agen-
cies: the US Food and Drug Administration (FDA), the
Medicines and Healthcare Products Regulatory Agency
(MHRA; UK), and the Medical Products Agency (MPA;
Sweden), at different stages of the study development.
MHRA and MPA were consulted after the protocol was fin-
ished but before the study’s standard operation procedure
(SAP) was written. Consultation with them was ultimately
responsible for the inclusion of the continuous variable
analyses.
Design of the POWER Trials
As mentioned above, two identical trials were designed to
evaluate the efficacy and safety of enobosarm for the preven-
tion and treatment of muscle wasting in patients with NSCLC
undergoing first-line platinum-based chemotherapy either
with a taxane (POWER 1) or non-taxane (POWER 2). A
range of potential standard chemotherapy regimens allow
the treatment of the study population to reflect standard of
care at the community level, including the most common che-
motherapy in this setting. Additionally, similar outcomes were
expected across these chemotherapy regimens in terms of tox-
icity and clinical response within each trial, reducing potential
heterogeneity associated with treatment within the taxane trial
and within the non-taxane trial. First-line treatment with tyro-
sine kinase inhibitors is prohibited in these studies to maintain
a homogenous patient population in terms of first-line chemo-
therapy and avoid any potential concerns related to the ability
of the tyrosine kinase inhibitors to exacerbate muscle wasting
[23]. Importantly, this exclusion criterion allows study partic-
ipation by the majority of patients with NSCLC undergoing
first-line treatment and allows subjects to receive tyrosine ki-
nase inhibitors if clinically warranted after potential tumor
progression during the trials (failed first-line chemotherapy).
As muscle wasting has multifactorial etiologies that differ
depending on the type of malignancy with which it is associ-
ated (pancreatic cancer vs head and neck cancer vs esophageal
cancer, as examples), the success of a phase 3 clinical trial
depends on further limiting heterogeneity by studying one
specific tumor type at a time. NSCLC was chosen as a repre-
sentative cancer for these phase 3 studies primarily because
lung cancer is the leading cause of cancer death in the western
world, including the USA [24] and up to 85–90 % of lung
cancer cases are NSCLC [25]. There were approximately 1.8
million new cases of lung cancer reported worldwide in 2012
[26]. Approximately 50 % of patients with NSCLC and great-
er than 60 % of men with NSCLC have already developed
severe muscle wasting by the time their malignancy is diag-
nosed [4]. Moreover, in the preceding phase 2b trial of
enobosarm in patients with NSCLC, significant losses in
LBM occurred over the course of the study (4 months) in
the placebo arm, while enobosarm improved physical function
and LBM.
Importantly, the FDA is in agreement with including
NSCLC as an appropriate cancer type to target in the phase
3 trial as these patients would likely present with a median
survival of a sufficient duration to measure the effect of the
therapy. As other cancer types are associated with more ag-
gressive muscle wasting (e.g., pancreatic cancer), the shorter
overall survival represents a potential challenge for a 5-month
intervention.
Patients
The full inclusion and exclusion criteria for POWER 1 and
POWER 2 can be found in Table 1. In short, postmenopausal
females and males >45 years of age with a diagnosis of stage
III or IV NSCLC prior to the initiation of first-line chemother-
apy are eligible. Subjects do not have to meet a minimum or
maximum amount of weight loss at baseline to be eligible for
the study. This allows the inclusion of patients with and with-
out muscle wasting prior to study entry, allowing for the eval-
uation of both prevention and treatment of this condition. The
trial was conducted in 60 academic and experienced commu-
nity sites in Eastern Europe, South America, and North
America.
Overall Study Design
POWER 1 and POWER 2 are identically designed, phase 3,
randomized, double-blind, placebo-controlled, multicenter,
multinational trials (Fig. 1). A total of 300 patients are to be
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enrolled into each study (see statistical section for details).
Randomization is as follows: 1:1 ratio to either placebo
(n=150) or enobosarm 3 mg (n=150), with patients stratified
to balance the distribution of first-line chemotherapy regi-
mens, gender, and NSCLC stage (III vs IV). Study treatment
will be administered orally once a day for up to 147 days, with
follow-up of only survival continuing after day 147.
Endpoints and Justification for Response Criteria
A comprehensive list of all efficacy and safety endpoints can
be found in Table 2. The co-primary endpoints were physical
function and LBM response assessed at baseline, day-42, day-
84, and day-147 visits. A patient is deemed to have a physical
function response if a ≥10 % increase in stair climb power at
the day-84 visit is observed as compared with baseline. This
threshold was established based on clinical meaningfulness
from previous literature [27, 28]. A patient is deemed to have
had a LBM response if their LBM at the day-84 visit is the
same as or higher than their LBM at baseline.
Rationale for Physical Function Tests
Physical function tests have been utilized in the approval of
medications to treat diseases associated with functional limi-
tations such as multiple sclerosis, pulmonary arterial hyper-
tension, and HIV-associated wasting [29–31].
The stair climb test was chosen for these trials based
on its association with everyday living and is associated
with strength, balance, mobility, speed, and endurance
[32]. The stair climb power has been a physical func-
tion method of choice on previously conducted clinical
studies in populations with or at risk for muscle loss
(including NSCLC patients). It is a simple and safe
measure associated with measures of lower-limb muscle
strength and power and functional performance in older
Table 1 POWER 1 and POWER
2 inclusion and exclusion criteria Inclusion Exclusion
•Voluntary, signed informed consent
•BMI ≤32 and weight <300 lb (<136 kg)
•Diagnosis of stage III or IV NSCLC
•First-line chemotherapy not yet started
•Planned first-line chemotherapy regimen is
platinum plus a taxane (POWER 1) or
platinum plus a non-taxane agent (POWER 2)
•Screening to occur ≥4 weeks (28 days)
postsurgery (in surgical cases)
•Life expectancy >6 months
•ECOG score ≤1
•Serum creatinine ≤2.0 mg/dL
•Men: aged ≥30 years
•Women: aged ≥30 years with clinical
confirmation of postmenopausal status
•Men: agree to use a double-barrier method of
contraception during and 3 months after study
•Men: serum PSA ≤4.0 ng/mL or biopsy
negative for prostate cancer within 6 months
•Clinically significant concurrent illness that would
interfere with protocol compliance or follow-up
(investigator judgment)
•ALT/SGPT or AST/SGOT >1.5 times the ULN without
and >5 times the ULN, evidence of liver metastases
•Alkaline phosphatase >3 times the ULN and/or total
bilirubin >2 mg/dL at baseline
•Biologic agents or kinase inhibitors in chemotherapy
regimen including, but not limited to bevacizumab,
gefitinib, and erlotinib
•Uncontrolled hypertension, congestive heart failure, or
angina
•Stage 4 chronic obstructive pulmonary disease
•HBsAg positive for hepatitis B, unless diagnosis was
>10 years prior to enrollment with no evidence of active
liver disease
•Positive screen for hepatitis C antibody, hepatitis A
antibody IgM, or HIV
•Use of testosterone, oxandrolone, testosterone-like
androgenic agents, or antiandrogens within 30 days of
study (requiring permission in cases of long-term depot
within 6 months)
•Current use of megestrol acetate, dronabinol, medical
marijuana, or any prescription medication intended to
increase appetite or treat unintentional weight loss
•Baseline stair climb time ≥30 s (mean of two stair climb
tests)
•Active cancer, other than NSCLC or nonmelanoma
carcinoma of the skin, within the past 2 years
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECOG Eastern
Cooperative Oncology Group, HBsAg hepatitis B surface antigen, IgM immunoglobulin M, NSCLC non-small
cell lung cancer, POWER Prevention and treatment Of muscle Wasting in patients with cancER, PSA prostate-
specific antigen, SGOT serum glutamic oxaloacetic transaminase, SGPT serum glutamic pyruvic transaminase,
ULN upper limit of normal
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adults [33]. Decreases in stair climb power in elderly
patients have been associated with detrimental changes
in balance and falls and morbidity and mortality, where-
as increases have been associated with improvements in
QOL [32].
Stair climb power is calculated as power (watts) =work/
time= force ×velocity. In addition to strength, it takes into
consideration a constellation of muscle-related attributes in-
cluding balance, mobility, and endurance [32]. Due to the
level of physical intensity required to climb stairs, increases
in stair climb power should equate to similar or greater im-
provements in other less physically intense daily activities that
are either short in duration or utilize smaller muscle groups
(i.e., walking a short distance, rising to a standing position
from a chair, or lifting or carrying household items).
Furthermore, the stair climb test is a direct measure and is a
well-accepted, reproducible, portable, and objective measure
of physical function [32].
Regardless of the physical function test used, thresholds of
clinically meaningful change have been established. A mini-
mally clinically meaningful change in physical function is a
5 % increase from baseline and a substantial clinically mean-
ingful change is a 10 % increase from baseline. Published
literature in healthy elderly and mobility limited subjects has
correlated measures of physical function with clinically mean-
ingful changes as established in the Short Physical
Performance Battery (SPPB). In a large randomized trial with
adults aged 70–89 (N=424) Kwon et al. utilized 400-m walk
and gait speed and demonstrated that a 4–4.5 % improvement
in physical function translates into Bminimally meaningful^
change while an improvement of 10 % represents a
Bsubstantial meaningful^ change [27]. Perera et al. showed
similar results with gait speed, 6-min walk distance, and
self-reported mobility in older adults with mobility disabilities
(N=492) concluding that an improvement in performance of
6–8% represents a Bsmall meaningful change^ and 11–17% a
Bsubstantial meaningful change^ [28]. These studies define
thresholds for Bminimally meaningful^ and Bsubstantial
meaningful^ clinical change that can be applied regardless
of the physical function test used.
Rationale for Body Composition Assessment
Although CT, MRI, and DXA are the methods of choice for
the assessment of lean and adipose tissue compartments
[34–39], DXA was selected as a method of choice for the
POWER trials due to its reliability and availability in clinical
settings (typically used for the assessment of osteoporosis and
its cost-efficiency with minimal radiation exposure) [40, 41].
Additionally, DXA measures are strongly correlated with the
state-of-the-art CT or MRI [42–46]. Since skeletal muscle is
such an important component of the LBM compartment,
changes in DXA-assessed LBM reflect changes in skeletal
muscle mass [39, 47].
LBM response is defined as no loss in LBM at the
day-84 visit compared to baseline. DXA scans of the
whole body are performed at approximately the same
time of day and by the same technician, with the patient
in a similar position using the same DXA scanner and
software version. DXA scans will be read centrally by
Synarc Imaging (www.synarc.com).
Fig. 1 POWER 1 and POWER 2 study design
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Additional Assessments
CT scans will also be performed at the days-84 and day-147
visits to assess tumor status, using contrast of the chest and
abdomen, including the liver and adrenal glands. If subjects
have brain metastases at baseline, CT or MRI will also be
assessed at these time points.
Quality of life will be assessed using five different tools:
the Functional Assessment of Anorexia and Cachexia
Therapies (FAACT-12®), the Functional Assessment of
Chronic Illness Therapy–Fatigue Scale (FACIT Fatigue
Scale®), Patient-Reported Outcomes Measurement
Information System (PROMIS®) Physical Functioning Short
Form 10a, PROMIS® Emotional Distress-Depression Short
Table 2 POWER 1 and POWER
2 endpoints Key Study day
US Food and Drug Administration: coprimary
10 % Increase in physical function via stair climb power 84
No loss of total LBM 84
MHRA/MPA: primary and key secondary
Change in physical function via stair climb power; continuous variable
analysis
Change in total LBM; continuous variable analysis
Secondary Study day
Physical function via stair climb power (day 84 responders only) 147
Total LBM (day 84 responders only) 147
Change in stair climb power from baselinea 84
Change in LBM from baselinea 84
Overall survival (data pooled from both studies) N/A
Tertiary Study day(s)
Healthcare resource utilization 0, 21, 42, 63, 84, 105, 126,
147
Percentage of adherence to baseline chemotherapy regimenb 21, 42, 63, 84, 105, 126, 147
Change in total body weight 0, 21, 42, 63, 84, 105, 126,
147
QOL via FAACT-12® 0, 42, 84, 147
QOL via FACIT Fatigue Scale® 0, 42, 84, 147
QOL via PROMIS® Physical Functioning Short Form 10a 0, 42, 84, 147
QOL via PROMIS® Emotional Distress-Depression Short Form 8b 0, 42, 84, 147
QOL via EQ-5D-5 L™ 0, 42, 84, 147
5 % Increase in physical function via stair climb power 84
Chemotherapy tolerability 21, 42, 63, 84, 105, 126, 147
Safety Study days
Routine safety assessments (adverse events, chemistries, urinalysisc,
hematology)
0, 21, 42, 63, 84, 105, 126,
147
Overall survival N/A
Serum hormone levels 0, 84, 147
Hair growth (women) 0, 84, 147
Serum PSA levels (men) 0, 21, 42, 63, 84, 105, 126,
147
ECOG status 84, 147
Tumor progression by RECIST 1.1 classification 84, 147
MHRAMedicines and Healthcare Products Regulatory Agency, MPAMedical Products Agency, ECOG Eastern
Cooperative Oncology Group, FAACT Functional Assessment of Anorexia and Cachexia Therapies, FACIT
Functional Assessment of Chronic Illness Therapy, QOL quality of life, PROMIS Patient-Reported Outcomes
Measurement Information System, PSA prostate-specific antigen, RECIST Response Evaluation Criteria In Solid
Tumors
aMean change to be calculated for each treatment arm
bChange from baseline includes initiation of second-line chemotherapy regimen
c Routine urinalysis was performed only on days 0, 84, and 147
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Form 8b, and the EQ-5D-5 L™ (Table 2). These QoL instru-
ments were intended to provide insights regarding how the
patients’ health, physical functioning, and ability to care for
themselves have been affected by their disease, as well as their
level of emotional distress and fatigue and perceptions about
the importance of various disease characteristics.
Statistical Methods
The two trials differ only in the choices of chemotherapy. Both
trials will evaluate the same endpoints of lean body mass and
stair climb power. After discussion with US and European
regulatory authorities, it was decided that different methods
of analysis of the SCP and LBM end points would be used in
the two regions.
For the US authorities, a responder analysis will be per-
formed for LBM and SCP as coprimary endpoints.
For European authorities, SCPwill be the primary endpoint
and LBM secondary. Both will be analyzed by longitudinal
analysis of percent change from baseline through days 84 and
147. Both analyses have different strengths and weaknesses,
but will be complementary to understanding the treatment
outcomes for enobosarm in the population and are further
described below.
The design proposed to US regulatory authorities is a re-
sponder analysis consisting of co-primary end points, one for
physical function and one for LBM. Physical function re-
sponse is defined as ≥10 % improvement from baseline to
day 84, and LBM response is defined as no loss of LBM from
baseline to day 84. Non-response is a failure to meet the re-
sponse definition or not having the day-84 assessment for any
reason. Missing data is accounted for by this definition of non-
response. The design assumes a proportion of response among
treated subjects of 0.20 above the control response proportion
for each of the physical function and LBM endpoints.
Retrospective application of the response definitions to the
subset of NSCLC subjects in the predecessor phase 2b trial
showed the maximum control response was 25 % for the
LBM endpoint (19 % for SCP); this was inflated to 30 %, that
the difference in the proportions responding to both end points
was approximately 0.20, and with other parameters α=0.05
and power=90 %, the sample size required was 124 subjects
per arm. Built into the computation above was the assumption
that 30% of subjects would be considered non-responders due
to missing the day 84 primary endpoint assessment. FDA
requested that the sample size be increased to 150 subjects
per arm for the purposes of the safety data base. The 0.20
difference in proportion of response between the two arms
covers a wide range of possible control response proportions
so that for control, response proportions from 0.20 to 0.75 all
have power >90 % to detect a 0.20 difference at α=0.05 with
150 subjects per arm. Specifically, at the aforementioned 0.30
control, response power is 93.3 %. Overall study success for
US purposes is defined as rejecting the null hypothesis for
both primary endpoints using a two-sided type I error proba-
bility of 0.05 for each. Considering the need for both co-
primaries to be statistically significant, the power for each trial
is at least 86.5 % under the assumption of no correlation be-
tween endpoints.
Each endpoint will be tested separately for significance
using a Monte Carlo approximation to the exact Cochran-
Mantel-Haenszel test stratified by chemotherapy regimen
(platinum plus paclitaxel or platinum plus docetaxel for
POWER 1 and platinum plus gemcitabine or platinum plus
pemetrexed or platinum plus vinorelbine for POWER 2), gen-
der, and cancer stage (III or IV). Importantly, a patient may be
a responder for one endpoint but not the other. Because all
subjects randomized and treated will have a response classifi-
cation, the primary analysis is intent-to-treat.
Analyses associated with the continuous form of the
data, rather than the dichotomous form of the data used
in the responder analyses, will be used to analyze sec-
ondary endpoints. As noted, the percentage change in
power will be the sole primary endpoint (stair climb
power) for European regulatory authorities. Random co-
efficients models (RCM)—also termed mixed model re-
peated measures (MMRM) analyses—will be used in
order to include all available data, including the day
42 assessment, for the physical function endpoint in-
cluding replicates, study day of assessment, treatment
arm, and the interaction between treatment arm and
study day of assessment. A significant interaction
(p < 0.05) would indicate significantly different slopes
(rates of change per day) between the enobosarm-
treated arm and the placebo arm. The same methodolo-
gy will be applied to the continuous form of the LBM
data; however, there are not replicates of DXA results at
each time point, unlike the physical function test. For
each of the physical function and LBM endpoints, an
MMRM analysis that compares the mean of post-
baseline measures between the two arms will be under-
taken as well. Hochberg’s methodology for controlling
alpha will be applied, so that, e.g., if the slope analysis
are not significant for say physical function, testing will
move to the post-baseline mean analysis but the alpha
level required for a significant result will be α= 0.025,
and the physical function endpoint will be considered
significant. Hierarchical testing will be used to control
alpha across all of the secondary endpoints so that if an
endpoint is deemed non-significant, i.e., both the slope
and post-baseline mean analyses are non-significant, for-
mal statistical testing will halt, and all further secondary
endpoints below that endpoint in the hierarchy will be
considered non-significant.
Responder analyses will be undertaken for QoL instru-
ments that have individual changes that are considered a
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response, as already described for the coprimary endpoints.
For quality-of-life instruments without a defined response,
appropriate parametric or nonparametric tests will be used to
compare differences in distributions. Additional sensitivity
and subgroup analyses are planned.
Survival analysis will be conducted as a predefined safety
endpoint of the clinical program to ensure that there was no
detrimental effect of enobosarm on the underlying cancer.
Additionally, the survival outcome data will be pooled to for-
mally assess superior survival in the enobosarm group com-
pared with placebo. The total number of patients expected for
the survival assessment is 600; the survival assessment is
event-driven and will require at least 450 deaths. Survival will
be estimated by the Kaplan–Meier method; differences in sur-
vival distributions will be compared with a stratified log-rank
test, stratified by chemotherapy (taxane, non-taxane; effec-
tively stratifying by trial), sex, and stage. It is projected that
the 450 deaths will be realized at approximately 2.84 years
after accrual of the first patient. Although the trials are not
prospectively powered to detect a survival difference, if me-
dian survival in the combined placebo arm is assumed to be
1 year and uniform accrual of all 600 patients occurs in 1 year
(both trials starting at approximately the same time), then the
test would have 86.6 % power to detect a hazard ratio of
≤0.75. The actual critical hazard ratio estimate of ≤0.831
would be associated with a significant (p<0.05) result and
lead to a conclusion of survival superiority.
Discussion and Conclusions
In light of the profound unmet medical need for the prevention
and treatment of muscle wasting in patients with cancer, a
number of agents, including SARMs, are under development
for patients with cancer who are prone to muscle wasting and
cachexia. The POWER trials for enobosarm are the first phase
3 clinical trials to assess a SARM for muscle wasting in pa-
tients with cancer and have addressed the need for novel study
design(s) with relevant endpoints to establish meaningful clin-
ical benefit for patients. Results from the POWER trials will
soon be released and will provide the first evidence collected
prospectively on the natural history of muscle wasting in pa-
tients receiving first-line chemotherapy and the magnitude
and impact of a SARM used for the treatment of muscle
wasting in NSCLC. Furthermore, results from the trials will
be used to critically evaluate the hereby described study
design.
POWER 1 and POWER 2 include subjects with no mini-
mum or maximum amount of weight loss at baseline so that
both prevention and treatment of muscle wasting can be
assessed as well as the prevalence of cachexia among these
patients according to recently proposed diagnostic criteria.
The majority of clinical trials investigating treatments for
muscle wasting or cachexia specify a minimum amount of
weight loss at baseline, limiting their ability to assess the pre-
ventive potential of a specific regimen [13–15, 31, 48–52].
The importance of prevention is underscored by evidence that
muscle wasting begins before the manifestation of any out-
ward clinical signs or symptoms, including overt weight loss
[53]. There is evidence to suggest that proteasome activity (an
indicator of protein degradation) was increased in muscle bi-
opsies taken from patients with gastric cancer, including pa-
tients who had not yet exhibited weight loss [54].
In addition to studying subjects who have not yet lost
weight, it is also important to characterize any changes in
weight that do occur throughout a study. Weight loss or gain
can reflect changes in adipose tissue, skeletal muscle, or both;
therefore, in order to determine whether an anabolic therapy is
affecting muscle wasting, it is necessary to measure changes
in body composition (i.e., LBM) at baseline and during treat-
ment (7, 8). As CT scans have been previously acquired as
part of the medical diagnosis/treatment (as discussed previ-
ously), an additional analysis of body composition by this
technique is being planned [55].
An additional aspect to be evaluated in the POWER trials
was the choice of functional assessments; including the stair
climb test and a variety of patient-reported mental, emotional,
social, and physical well-being instruments. Although defined
by loss in muscle mass, much of the burden of cachexia is due
to loss of function that is reflected in poor outcomes on the
aforementioned functional parameters. A palliative approach
addresses these by focusing on both the disease and symptoms
caused by the disease, within a patient/family-focused model
[56]. For this reason, the POWER trials incorporate a wide
variety of tests of functioning and QoL—such as stair climb
power and five separate QoL tools—to illuminate the full
range of each cancer patient’s experience in light of cancer-
driven cachexia [18, 19]. In the phase 2b study of enobosarm,
LBM increased significantly in the 1- and 3-mg treatment
groups; stair climb results also improved from baseline, by
18.0 % in the 1-mg arm and by 21.7 % in the 3-mg arm
[22••]. The use of coprimary endpoints related to LBM and
stair climb performance in the POWER studies may allow
more definitive analysis of the relationship between these
two measures.
It has been shown that initiating palliative care measures
early during cancer disease trajectory can result in prolonged
survival and clinically meaningful improvements in QoL and
mood in patients with advanced NSCLC [57]. While the pri-
mary objectives of the POWER studies deal with body com-
position and physical function, tumor progression and overall
survival data will also be of great interest. Although
enobosarm is being studied for the prevention and treatment
of muscle wasting, the potential interplay between muscle
wasting and disease progression may be of interest in these
trials and in future supporting studies [58].
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The POWER trials include patients with NSCLC as the
first population for treatment with enobosarm, but patients
with other cancer types may also benefit from enobosarm for
muscle wasting, which awaits confirmation in additional tri-
als. Cancer is a highly catabolic condition and typically more
severely manifested in colorectal, gastrointestinal, and pancre-
atic cancers even prior to the initiation of chemotherapy [59],
making patients with these tumor types of particular interest
for future muscle wasting and cachexia trials.
While the design of the POWER trials assesses the ability
of enobosarm to prevent and treat muscle wasting in a popu-
lation being treated with standard chemotherapy, future re-
search may be warranted to include patients using newer,
more targeted therapies. For example, with the approval of
several tyrosine kinase inhibitors, in lung cancer, renal cell
carcinoma, and other malignancies, it remains to be deter-
mined whether a SARM can benefit patients receiving these
treatments. Furthermore, it has been found that these targeted
cancer treatments themselves may be associated with muscle
wasting, so carefully controlled studies in these settings will
be needed [23].
As research in muscle wasting disorders progresses, we
may see the advent of combination therapy regimens. Since
there are both hypoanabolic and hypercatabolic processes at
work in cachexia in a multifactorial fashion, it may be prudent
to study the effects of combining an anabolic agent with an
antagonist of catabolic mediators [60]. Given that the best
outcome would be prevention of muscle wasting, and hence
cancer cachexia, future research should focus on both preven-
tion and treatment of this condition. It is anticipated that out-
comes from the POWER 1 and POWER 2 trials will be a
critical step in not only addressing a pressing unmet medical
need for additional supportive care, but also significantly
informing future research directions for enobosarm and other
trials. Notably, several underlying clinical conditions can re-
sult in muscle wasting with and without associated cachexia,
such as acquired immune deficiency syndrome (AIDS),
chronic heart failure, chronic obstructive pulmonary disease
(COPD), chronic renal failure, chronic infection and sepsis,
and cancer [7, 61], all of which can benefit from anabolic
therapy.
POWER 1 and POWER 2 Trial Status
The POWER studies were conceived and designed in 2011,
and recruitment commenced the same year. Recruitment was
completed in 2013, with results being prepared for
publication.
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